Description

The total viewing time for this session is approximately 1 hour 20 minutes. To view individual talks from within the Assessment session, please refer to the following timings:

• Overview, objectives, agenda and disclosures – 00:00:00 to 00:03:49
• Taking the decision to start therapy (Sérgio B. Sousa) – 00:03:50 to 00:23:48
• Defining and communicating expectations (Geneviève Baujat) – 00:23:49 to 00:45:53
• Q&A 00:45:54 to 00:53:59
• Case study: Assessment (Geneviève Baujat) – 00:54:00 to 01:04:26
• Q&A – 01:04:27 to 01:17:36
• Closing remarks – 01:17:37 to 1:19:51

This video is for viewing by healthcare professionals only.

VOXZOGO®▼ (vosoritide) is indicated for the treatment of achondroplasia in patients 2 years of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing. If you would like to view the current abbreviated prescribing information, please visit https://www.achondroplasia.expert/prescribing-information.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported to drugsafety@bmrn.com.
For general questions about BioMarin disease areas or products, contact medinfoeu@bmrn.com.

Date of preparation: November 2022; EU-VOX-00738